Missed Abortion. Missed abortion
Conditions
Interventions
Intervention 1: Intervention group: Participants in this group receive oral letrozole at a dose of 10 milligrams per day for three consecutive days. Following the completion of letrozole administratio
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women Admitted to the Hospital with a Diagnosis of Missed Abortion Gestational Age = 20 Weeks and = 50 Days (Based on the First Sonography) Age = 18 Years Old General Health Status Sufficient for Study Participation Hemoglobin Level = 10 g/dL Diastolic Blood Pressure < 95 mmHg
Exclusion criteria
Exclusion criteria: History of Adrenal Disease, Cancer, Porphyria, Severe or Recurrent Liver Disease, Asthma, Thromboembolic Diseases Patients With Blood Pressure = 130/80 mmHg History of Giving Birth to a Baby With Congenital Anomalies Breastfeeding Regular and Active Use of Prescribed, Hormonal, and Interfering Medications Prior to Study Entry Use of Intrauterine Device (IUD) Any Abnormalities in Baseline Tests Including: CBC, PT, PTT, INR, Urea, Creatinine, Na, K, Ca, Cl, Albumin, Fibrinogen, AST, ALT, ALP, Bili T, Bili D Symptoms of Allergy to any of the Prescribed Medications Unwillingness to Continue Participating in the Study or Withdrawing from Treatment at any Stage Failure to Attend Scheduled Follow-ups or Loss of Contact With the Research Team Heavy or Uncontrolled Vaginal Bleeding at any Point During the Intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of complete uterine evacuation, assessed via post-treatment transvaginal ultrasound. Timepoint: At baseline (Day 0): Prior to the intervention, transvaginal ultrasound is used to confirm the diagnosis of missed abortion. 48 hours after the last dose of misoprostol: Transvaginal ultrasound is used to assess for complete uterine evacuation. Method of measurement: Transvaginal ultrasound performed by an obstetrics and gynecology specialist using a transvaginal ultrasound probe to assess retained products of conception within the uterine cavity. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArvin Mahmoodi
Bandare-abbas University of Medical Sciences
Outcome results
None listed